Alberta Investment Management Corp acquired a new position in Penumbra, Inc. (NYSE:PEN - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 33,120 shares of the company's stock, valued at approximately $10,458,000. Alberta Investment Management Corp owned approximately 0.08% of Penumbra as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in PEN. Hsbc Holdings PLC grew its holdings in Penumbra by 2.3% during the 4th quarter. Hsbc Holdings PLC now owns 1,527 shares of the company's stock valued at $475,000 after buying an additional 35 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Penumbra by 27.1% in the 4th quarter. Farther Finance Advisors LLC now owns 178 shares of the company's stock valued at $55,000 after buying an additional 38 shares during the period. Swiss Life Asset Management Ltd grew its holdings in Penumbra by 2.3% in the fourth quarter. Swiss Life Asset Management Ltd now owns 1,728 shares of the company's stock valued at $537,000 after purchasing an additional 39 shares during the period. Keybank National Association OH increased its holdings in shares of Penumbra by 1.2% during the 4th quarter. Keybank National Association OH now owns 3,705 shares of the company's stock worth $1,152,000 after buying an additional 43 shares during the last quarter. Finally, UMB Bank n.a. increased its stake in Penumbra by 11.3% during the fourth quarter. UMB Bank n.a. now owns 442 shares of the company's stock worth $137,000 after acquiring an additional 45 shares during the last quarter. 88.88% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on the stock. Wall Street Zen raised shares of Penumbra to a "hold" rating in a research note on Saturday, May 9th. Zacks Research lowered shares of Penumbra from a "hold" rating to a "strong sell" rating in a research note on Monday, June 29th. Royal Bank Of Canada restated a "sector perform" rating and set a $374.00 price objective on shares of Penumbra in a research note on Thursday, June 11th. Evercore restated an "outperform" rating and issued a $320.00 price target on shares of Penumbra in a research report on Monday, July 6th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Penumbra in a report on Friday, July 17th. Three analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $367.07.
Get Our Latest Report on PEN
Penumbra Trading Down 0.0%
Penumbra stock opened at $326.91 on Monday. Penumbra, Inc. has a 12-month low of $221.26 and a 12-month high of $362.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.75 and a quick ratio of 3.86. The stock has a market capitalization of $12.88 billion, a PE ratio of 80.32, a price-to-earnings-growth ratio of 2.03 and a beta of 0.70. The firm has a 50 day simple moving average of $319.53 and a 200-day simple moving average of $328.64.
Penumbra (NYSE:PEN - Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.88 earnings per share for the quarter, missing analysts' consensus estimates of $1.16 by ($0.28). Penumbra had a return on equity of 10.50% and a net margin of 10.67%.The firm had revenue of $390.05 million during the quarter, compared to analyst estimates of $389.64 million. During the same quarter last year, the company earned $0.86 earnings per share. The business's revenue for the quarter was up 14.9% on a year-over-year basis. As a group, equities research analysts expect that Penumbra, Inc. will post 5.02 EPS for the current fiscal year.
About Penumbra
(
Free Report)
Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra's technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.
At the core of Penumbra's portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.
Featured Articles
Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Penumbra, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list.
While Penumbra currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
